Hemoglobinopathies such as the sickle cell disorders and thalassemias tend to affect mainly people from certain ethnic minority groups.
As we have seen, screening and prenatal diagnosis are used for thalassemia.
The question remains, however, of how to mediate between autonomy and other goals, such as public health, and welfare of those currently alive who suffer from thalassemia.
One such disease— thalassemia— can now be identified in the foetus as a result of early work on embryonic tissue.
I refer to those who suffer from inherited blood disorders such as sickle sell anaemia or thalassemia major and related haemoglobin disorders.
People with thalassemia make less hemoglobin and have fewer circulating red blood cells than normal, which results in mild or severe anemia.
All thalassemia patients are susceptible to health complications that involve the spleen (which is often enlarged and frequently removed) and gallstones.
In contrast, membrane excess is only relative in patients with iron-deficiency anemia and thalassemia because of the reduced quantity of intracellular hemoglobin.
